Sign up
Pharma Capital

Avalon GloboCare to produce its first series of clinical-grade exosome products by end of 2019

Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr. David Jin tells Proactive Investors that the biotech company will be producing its first series of clinical grade exosome products, used for skincare and hair growth, by the second half of 2019.

Dr. Jin adds that the New Jersey-based company is collaborating with the Massachusetts Institute of Technology to develop an AI-enhanced protein design technology, which will allow the company to innovate in new cell therapy techniques.

 

View full AVCO profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.